FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer (mRCC).
J. L. Chen
No relevant relationships to disclose
D. E. Appelbaum
No relevant relationships to disclose
M. Kocherginsky
Research Funding - Novartis
* K. Rathmell
Consultant or Advisory Role - AVEO; Novartis; Wyeth
Honoraria - Bayer; Onyx
Research Funding - Bayer; Onyx
D. F. McDermott
Consultant or Advisory Role - Biogen Idec; Bristol-Myers Squibb; Genentech; Prometheus; Roche
W. M. Stadler
Consultant or Advisory Role - Novartis